Gilead and Kite Oncology to present latest blood cancer research at the European Hematology Association (EHA) 2022 CongressSub-analyses from Kite’s ZUMA-7 study of CAR T cell therapy in second-line diffuse large B cell lymphoma includes data in patients over 65 and by tumour burden characteristicsLonger-term d.
Kite’s Landmark CAR T-Cell Therapy Study ZUMA-7 in RelapsedRefractory Large B-Cell Lymphoma to be Featured in ASH Plenary Session – – Five Oral Presentations Highlight Kite’s Leadership in CAR T-Cell Therapies – – New Research on Magrolimab Provides Key Insights as Gilead Rapidly Expands Research in AML – Gilead Sciences, Inc. and Kite, a Gilead Company, today announced that data at the 63rd American .
Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer
SBLA Currently Under Review by the U.S. FDA for Full Marketing Approval in mTNBC Gilead Sciences, Inc. is presenting new data from the Phase 3 ASCENT trial of Trodelvy ® in metastatic triple-negative breast cancer at the 2020 San Antonio Breast Cancer Symposium being held virtually December 8-11, 2020. The new data and analyses from the ASCENT trial continue to demonstrate the high clinical activity of Trodelvy … sBLA Currently Under Review by the U.S. FDA for Full Marketing Approval in mTNBC Gilead Sciences, Inc. (Nasdaq: GILD) is presenting new data from the Phase 3 ASCENT trial of Trodelvy